Ibruxen 140 mg, also known as Ibrutinib, is a medication primarily prescribed for the treatment of certain types of blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. It belongs to a class of drugs called Bruton's tyrosine kinase inhibitors, which work by blocking the action of an enzyme involved in the growth and survival of cancer cells. Ibruxen is typically taken orally once daily, with or without food. Common side effects may include diarrhea, nausea, fatigue, and infections. Serious side effects such as bleeding, heart rhythm abnormalities, and high blood pressure may also occur. Patients should be closely monitored by their healthcare provider while taking Ibruxen. Overall, Ibruxen 140 mg plays a crucial role in the treatment of certain blood cancers, helping to slow disease progression and improve patient outcomes.